Magic mushroom compound tested for tough depression and addiction

NCT ID NCT07499583

Not yet recruiting Symptom relief Sponsor: Indiana University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a single dose of psilocybin (the active ingredient in magic mushrooms) combined with psychotherapy is safe and can reduce depression and substance use in veterans and first responders who haven't responded to standard treatments. Fifty participants will receive one of three doses (5mg, 10mg, or 25mg) and complete therapy sessions before and after. The trial also looks at brain changes and side effects over 14 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: psilocybin
What this could lead to: If it works, this could point toward a new treatment option for people with hard-to-treat depression and substance use problems.
What could go wrong: This is an early-phase trial with only 50 participants, so results may not apply to everyone. Psilocybin can cause temporary anxiety or confusion during the dosing session.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SUBSTANCE USE DISORDERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depressive Disorder, Treatment-Resistant substance-related disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SUBSTANCE USE DISORDERS TREATMENT RESISTANT DEPRESSION

Contacts and locations

Locations

Goodman Hall, Dept of Psychiatry, Indiana University

Indianapolis, Indiana, 46202-3082, United States
The Stark Neuroscience Building (Goodman Hall)

Indianapolis, Indiana, 46202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.